Compare Packaging Corporation of America (PKG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Packaging Corp of America (PKG) trades at $228.43, down 1.99% on the day, with a bullish technical signal supported by moving averages. The company maintains solid fundamentals with $8.99B revenue and 8.04% net margin, though recent earnings show mixed performance with Q1 2026 beating estimates but Q3/Q4 2025 missing. A 20% dividend increase to $6.00 annually reflects management confidence. Analyst consensus is mixed with 34.62% buy ratings and a $256.14 price target suggesting 12% upside potential.

PKG presents a balanced investment case with attractive dividend yield and analyst upside, but faces earnings volatility and margin pressure. The upcoming Q2 2026 earnings report on July 22 will be crucial for confirming growth trajectory. Key risks include integration challenges from the Greif acquisition and ongoing cost pressures affecting profitability.

Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.

The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.